Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Wang, Zhongqiu ^a,b   Sturgis, Erich M ^a   Zhang, Fenghua ^a,c   Lei, Dapeng ^a,d,e   Liu, Zhensheng ^a   Xu, Li ^a   Song, Xicheng ^a,f   Wei, Qingyi ^a   Li, Guojun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HEBEI GENERAL HOSPITAL   (China)

^d SHANDONG UNIVERSITY   (China)

^e BEIJING HOSPITAL   (China)

^f YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Genetic susceptibility; P21; P27; Polymorphism; Second primary malignancy; Squamous cell carcinoma of head and neck

Indexed keywords

GUANINE; PROTEIN P21; PROTEIN P27; THYMINE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HEAD AND NECK CARCINOMA; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; SECOND CANCER; SQUAMOUS CELL CARCINOMA; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED;

CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, GENETIC;

EID: 84862818660     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-17     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156. 10.1002/ijc.1440, 11668491.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
3. Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol 2011, 29:3503-3509. 10.1200/JCO.2011.35.7301, 21844503.
4. Day GL, Blot WJ, Shore RE, McLaughlin JK, Austin DF, Greenberg RS, Liff JM, Preston-Martin S, Sarkar S, Schoenberg JB, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 1994, 86:131-137. 10.1093/jnci/86.2.131, 8271296.
5. Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Spitz MR. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 2004, 101:2837-2842. 10.1002/cncr.20714, 15536619.
6. Ng AK, Travis LB. Second primary cancers: an overview. Hematol Oncol Clin North Am 2008, 22:271-289. vii, 10.1016/j.hoc.2008.01.007, 18395150.
7. Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope 2005, 115:2221-2231. 10.1097/01.mlg.0000183736.96004.f7, 16369171.
8. Minard CG, Spitz MR, Wu X, Hong WK, Etzel CJ. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer 2006, 106:2636-2644. 10.1002/cncr.21928, 16703596.
9. Li F, Sturgis EM, Zafereo ME, Liu Z, Wang LE, Wei Q, Li G. p73 G4C14-to-A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck. Int J Cancer 2009, 125:2660-2665. 10.1002/ijc.24570, 2757513, 19585505.
10. Zafereo ME, Sturgis EM, Liu Z, Wang LE, Wei Q, Li G. Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis 2009, 30:997-1002. 10.1093/carcin/bgp096, 2691145, 19369580.
11. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512. 10.1101/gad.13.12.1501, 10385618.
12. He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer 2006, 95:1514-1524. 10.1038/sj.bjc.6603448, 2360737, 17088910.
13. Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR, Wei Q. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2005, 26:1596-1602. 10.1093/carcin/bgi105, 15878916.
14. Figueiredo JC, Knight JA, Cho S, Savas S, Onay UV, Briollais L, Goodwin PJ, McLaughlin JR, Andrulis IL, Ozcelik H. Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer 2007, 7:99. 10.1186/1471-2407-7-99, 1906827, 17567920.
15. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J, Goodfellow PJ. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003, 63:2033-2036.
16. Schondorf T, Eisele L, Gohring UJ, Valter MM, Warm M, Mallmann P, Becker M, Fechteler R, Weisshaar MP, Hoopmann M. The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients. Tumour Biol 2004, 25:306-312. 10.1159/000081396, 15627896.
17. Li G, Sturgis EM, Wang LE, Chamberlain RM, Spitz MR, El-Naggar AK, Hong WK, Wei Q. Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clin Cancer Res 2004, 10:3996-4002. 10.1158/1078-0432.CCR-04-0089, 15217930.
18. Lei D, Sturgis EM, Liu Z, Zafereo ME, Wei Q, Li G. Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis 2010, 31:222-227. 10.1093/carcin/bgp279, 2812571, 19955391.
19. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999, 154:313-323. 10.1016/S0002-9440(10)65277-7, 1850003, 10027389.
20. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008, 10:e19. 2678956, 18590585.
21. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994, 8:9-22. 10.1101/gad.8.1.9, 8288131.
22. Choi HR, Tucker SA, Huang Z, Gillenwater AM, Luna MA, Batsakis JG, El-Naggar AK. Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis. Int J Oncol 2003, 22:409-414.
23. Koufos A, Grundy P, Morgan K, Aleck KA, Hadro T, Lampkin BC, Kalbakji A, Cavenee WK. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989, 44:711-719. 1715635, 2539717.
24. Kuropkat C, Rudolph P, Frahm SO, Parwaresch R, Werner JA. Proliferation marker Ki-S11-a prognostic indicator for squamous cell carcinoma of the hypopharynx. Virchows Arch 1999, 435:590-595. 10.1007/s004280050445, 10628801.
25. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995, 55:2266-2269.
26. Mineta H, Miura K, Suzuki I, Takebayashi S, Amano H, Araki K, Harada H, Ichimura K, Wennerberg JP, Dictor MR. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 1999, 85:1011-1017. 10.1002/(SICI)1097-0142(19990301)85:5<1011::AID-CNCR1>3.0.CO;2-0, 10091782.
27. Kudo Y, Takata T, Ogawa I, Zhao M, Sato S, Takekoshi T, Miyauchi M, Nikai H. Reduced expression of p27(Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma. Cancer Lett 2000, 151:217-222. 10.1016/S0304-3835(99)00419-X, 10738117.
28. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369:574-578. 10.1038/369574a0, 7911228.
29. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704. 10.1038/366701a0, 8259214.
30. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 2001, 61:7122-7129.
31. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002, 179:1-14. 10.1016/S0304-3835(01)00847-3, 11880176.
32. Pruneri G, Pignataro L, Carboni N, Buffa R, Di Finizio D, Cesana BM, Neri A. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol 1999, 17:3150-3159.
33. Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, et al. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res 2008, 14:4010-4015. 10.1158/1078-0432.CCR-07-4187, 18559624.
34. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C, et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007, 67:3027-3035. 10.1158/0008-5472.CAN-06-3261, 17409409.
35. Kong S, Wei Q, Amos CI, Lynch PM, Levin B, Zong J, Frazier ML. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 2001, 93:1106-1108. 10.1093/jnci/93.14.1106, 11459873.
36. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999, 398:160-165. 10.1038/18230, 10086358.
37. Lee J, Kim SS. The function of p27KIP1 during tumor development. Exp Mol Med 2009, 41:765-771. 10.3858/emm.2009.41.11.102, 2788730, 19887899.
38. Chedid M, Michieli P, Lengel C, Huppi K, Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 1994, 9:3021-3024.
39. Rastinejad F, Blau HM. Genetic complementation reveals a novel regulatory role for 3' untranslated regions in growth and differentiation. Cell 1993, 72:903-917. 10.1016/0092-8674(93)90579-F, 8384533.
40. Rastinejad F, Conboy MJ, Rando TA, Blau HM. Tumor suppression by RNA from the 3' untranslated region of alpha-tropomyosin. Cell 1993, 75:1107-1117. 10.1016/0092-8674(93)90320-P, 7505203.
41. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 1932, 51:1358.